The contemporary role of metastasectomy in the management of metastatic RCC

Abstract

Metastasectomy was initially described in the 1970s as a therapeutic strategy for patients with metastatic renal cell carcinoma. Since that time, systemic therapy options have grown exponentially, most recently with the introduction of immunotherapy. We aimed to review the contemporary literature regarding the role of metastasectomy in the era of targeted therapy and immunotherapy. Historically, metastasectomy has benefited patients with small volume, single-organ metastases, with favorable outcomes amongst younger, healthier patients with metastases to specific sites. The interplay between the employment of metastasectomy and systemic therapy has been limited to small, retrospective series with significant patient selection bias. More recently, investigators have conducted randomized controlled trials exploring the use of targeted therapies in the adjuvant setting after metastasectomy. Initial randomized data suggested no benefit in using sorafenib in this setting, and a subsequent study demonstrated possible harm in using pazopanib after metastasectomy. However, the role of other novel systemic therapies, including immunotherapy, nor the timing of use, have been meaningfully explored. Metastasectomy appears to be a valuable therapeutic option in the properly selected patient, requiring a multi-disciplinary management strategy and, pending future trials, a multimodal treatment approach.

Keywords

Clear-cell metastatic renal cell carcinoma / metastasectomy / immunotherapy

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[2] Capitanio U.Renal cancer.Lancet2016;387:894-906

[3] Motzer RJ,Boyle S.NCCN guidelines insights: kidney cancer, version 1.2021.J Natl Compr Canc Netw2020;18:1160-70

[4] Zaid HB,Safdar NS.Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.J Urol2017;197:44-9

[5] Soares A,Maluf FC.Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).J Cancer Res Clin Oncol2020;146:1829-45 PMCID:PMC7256074

[6] Kavolius JP,Pavlovich C,Burt ME.Resection of metastatic renal cell carcinoma.J Clin Oncol1998;16:2261-6

[7] der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis.Eur Urol1999;35:197-203

[8] Alt AL,Lohse CM,Leibovich BC.Survival after complete surgical resection of multiple metastases from renal cell carcinoma.Cancer2011;117:2873-82

[9] Ng CS,Silverman PM,Tamboli P.Renal cell carcinoma: diagnosis, staging, and surveillance.AJR Am J Roentgenol2008;191:1220-32

[10] Vikram R,Blaufox MD.ACR appropriateness criteria renal cell carcinoma staging.J Am Coll Radiol2016;13:518-25

[11] Win AZ.Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience.World J Nucl Med2015;14:36-40 PMCID:PMC4337006

[12] Verhoeff SR,Boon E.Lesion detection by [⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.Eur J Nucl Med Mol Imaging2019;46:1931-9

[13] Pfannschmidt J,Muley T,Trainer C.Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma.Ann Thorac Surg2002;74:1653-7

[14] Bölükbas S,Eberlein M,Schirren J.The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.Thorac Cardiovasc Surg2012;60:390-7

[15] Kudelin N,Eberlein M.Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience.Ann Thorac Surg2013;96:265-70: discussion 270-1

[16] Saricam M.Factors affecting long-term survival following pulmonary metastasectomy of renal cell carcinoma.Urol J2020;17:492-6

[17] Kume H,Yamada Y.Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?.J Urol2011;185:1611-4

[18] Huang Z,Zhang X,Liu S.Clear cell renal cell carcinoma bone metastasis: what should be considered in prognostic evaluation.Eur J Surg Oncol2019;45:1246-52

[19] Kollender Y,Price WM.Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention.J Urol2000;164:1505-8

[20] Higuchi T,Hayashi K.Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma.Bone Joint J2018;100-B:1241-8

[21] Lin PP,Lewis VO.Patient survival after surgery for osseous metastases from renal cell carcinoma.J Bone Joint Surg Am2007;89:1794-801

[22] Ptashnikov D,Kostrickii S.Metastasectomy and targeted therapy for patients with spinal metastases of renal cell carcinoma.Int J Spine Surg2020;14:982-8 PMCID:PMC7872394

[23] Amini A,Bourlon MT.Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?.Pract Radiat Oncol2015;5:e589-96 PMCID:PMC4706456

[24] Jhaveri PM,Paulino AC.A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases.Acta Oncol2012;51:584-8

[25] Martel G,Canil C.Surgical management of genitourinary cancer liver metastases.Surg Oncol Clin N Am2021;30:89-102

[26] Ruys AT,Nagtegaal ID.Surgical treatment of renal cell cancer liver metastases: a population-based study.Ann Surg Oncol2011;18:1932-8 PMCID:PMC3115064

[27] Staehler MD,Haseke N.Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.World J Urol2010;28:543-7

[28] Joyce DD,Groeschl RT.Complications and outcomes associated with surgical management of renal cell carcinoma involving the liver: a matched cohort study.Urology2017;99:155-61

[29] Wroński M,Russo P.Surgical resection of brain metastases from renal cell carcinoma in 50 patients.Urology1996;47:187-93

[30] Capitanio U,Blute ML.Lymph node dissection in renal cell carcinoma.Eur Urol2011;60:1212-20

[31] Blom JH,Maréchal JM.EORTC Genitourinary Tract Cancer GroupRadical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.Eur Urol2009;55:28-34

[32] Pantuck AJ,Dorey F.Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.J Urol2003;169:2076-83

[33] Feuerstein MA,Bernstein M.Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis.Int J Urol2014;21:874-9 PMCID:PMC4146659

[34] Gershman B,Moreira DM.Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis.Eur Urol2017;71:560-7

[35] John NT,Hakimi AA.Role of lymph node dissection in renal cell cancer.Urol Oncol2019;37:187-92

[36] Ouzaid I,Staehler M.Young Academic Urologists Kidney Cancer Working Group of the European Association of UrologySurgical metastasectomy in renal cell carcinoma: a systematic review.Eur Urol Oncol2019;2:141-9

[37] Ishihara H,Kondo T.Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.Urol Oncol2021;39:77.e17-25

[38] Takagi T,Ishihara H.Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era.Urol Oncol2020;38:515-20

[39] Palumbo C,Knipper S.Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy: a combined population-based analysis.Anticancer Res2019;39:4357-61

[40] Meyer CP,Karam JA.Complications after metastasectomy for renal cell carcinoma-a population-based assessment.Eur Urol2017;72:171-4

[41] Karam JA,Varella L.Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.J Urol2011;185:439-44 PMCID:PMC4668716

[42] Li JR,Yang CK.The impact of local intervention combined with targeted therapy on metastatic renal cell carcinoma.Anticancer Res2018;38:5339-45

[43] Procopio G,Cognetti F.Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study.Eur Urol Oncol2019;2:699-707

[44] Appleman LJ,Pal SK.Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810).J Clin Oncol2019;37:4502

[45] Rausch S,Hennenlotter J.Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a patient-specific adjuvant multi-peptide vaccine after resection of metastases.Eur Urol Focus2019;5:604-7

[46] Ishihara H,Kondo T,Yoshida K.Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?.Int J Urol2020;27:691-2

[47] Dragomir A,Wood LA.Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.Urol Oncol2020;38:799.e1-799.e10

[48] Lyon TD,Shah PH.Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era.J Urol2020;203:275-82

[49] Flanigan RC,Blumenstein BA.Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.N Engl J Med2001;345:1655-9

[50] Mickisch G,van Poppel H,Sylvester R.Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.Lancet2001;358:966-70

[51] Méjean A,Thezenas S.Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma.N Engl J Med2018;379:417-27

[52] Massari F,Gatto L.Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma?.Target Oncol2018;13:705-14

[53] Bex A,Jewett M.Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial.JAMA Oncol2019;5:164-70 PMCID:PMC6439568

[54] Bhindi B,Albiges L.Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma.Eur Urol2019;75:111-28

[55] Gao J,Tannir NM.A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or posttreatment biopsy (Bx).J Clin Oncol2018;36:4520

[56] Singla N,Ghandour RA.Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.Urol Oncol2020;38:604.e9-604.e17 PMCID:PMC7269798

[57] Liu J,Yong MC.Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.Cancer Discov2016;6:1382-99

[58] Clark DJ,Petralia F.Clinical Proteomic Tumor Analysis ConsortiumIntegrated proteogenomic characterization of clear cell renal cell carcinoma.Cell2020;180:207

[59] Ricketts CJ.Intratumoral heterogeneity in kidney cancer.Nat Genet2014;46:214-5 PMCID:PMC4193312

[60] Miao D,Gao W.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Science2018;359:801-6 PMCID:PMC6035749

[61] Verbiest A,Job S.Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy.Eur Urol2018;74:474-80

[62] Patel HD,Shuch BM.The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?.Future Oncol2019;15:1683-95 PMCID:PMC6595543